STOCK MARKET BSE NSE

Hyderabad firm awaits approval for Covid injection trial

A Hyderabad-based company applied for a patent and clinical trial approval for a first-of-its-kind immunoglobulin Covid-19 injection — a treatment method similar to plasma therapy.

Published: 30th April 2020 12:58 AM  |   Last Updated: 30th April 2020 10:48 AM   |  A+A-

Covid injection trial

Covid injection trial

By Express News Service

HYDERABAD: A Hyderabad-based company applied for a patent and clinical trial approval for a first-of-its-kind immunoglobulin Covid-19 injection — a treatment method similar to plasma therapy. The company recently finished theoretical research and hopes to get the approval for trials within a week.

Speaking to Express, Dr Sreehari Y, chairman of MRPA Corporation, said, “We started work on the research three months ago when the first Covid-19 case was reported in China. We have a team of 25 doctors, including general physicians, pathologists and microbiologists, among others”. 

He further said, “The basic process of this injection is that Injectable Immunoglobulins are collected from asymptomatic Covid-19 persons (IgG antibodies positive) or recovered patients to protect and strengthen the immune system of new patients.

Different procedures may be used to filter immunoglobulins from the blood”.Is the procedure similar to the much-talked-about plasma therapy? “The concept is similar, but in plasma therapy if one gives a dose of 200ml plasma, there is no way of adjusting it. Hence, it did not succeed. But ,with Human Covid-19 Injection, the dosage of immunoglobulins can be adjusted as per the severity of the case,” Dr Sreehari said.


Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

IPL_2020
flipboard facebook twitter whatsapp